Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) – HC Wainwright lifted their FY2022 earnings estimates for Repare Therapeutics in a research report issued to clients and investors on Thursday, November 17th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.88) per share for the year, up from their previous forecast of ($3.71). HC Wainwright has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Repare Therapeutics’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Repare Therapeutics’ Q4 2022 earnings at ($0.95) EPS, Q1 2023 earnings at ($0.98) EPS, Q2 2023 earnings at ($1.01) EPS, Q3 2023 earnings at ($1.03) EPS, Q4 2023 earnings at ($1.06) EPS and FY2023 earnings at ($4.07) EPS.
Separately, Morgan Stanley reduced their price objective on Repare Therapeutics from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, August 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.50.
Repare Therapeutics Trading Up 2.3 %
NASDAQ:RPTX opened at $18.13 on Monday. The stock has a 50 day moving average of $13.83 and a 200-day moving average of $12.88. The firm has a market capitalization of $760.77 million, a PE ratio of -24.84 and a beta of 0.02. Repare Therapeutics has a 52 week low of $8.06 and a 52 week high of $27.95.
Institutional Trading of Repare Therapeutics
Several hedge funds have recently added to or reduced their stakes in RPTX. Deep Track Capital LP increased its holdings in shares of Repare Therapeutics by 26.9% during the first quarter. Deep Track Capital LP now owns 2,664,017 shares of the company’s stock valued at $37,936,000 after purchasing an additional 564,017 shares during the period. Affinity Asset Advisors LLC raised its position in shares of Repare Therapeutics by 72.5% during the 1st quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock worth $6,677,000 after buying an additional 197,127 shares in the last quarter. BlackRock Inc. raised its position in shares of Repare Therapeutics by 1.9% during the 1st quarter. BlackRock Inc. now owns 467,311 shares of the company’s stock worth $6,655,000 after buying an additional 8,680 shares in the last quarter. Sectoral Asset Management Inc. lifted its stake in shares of Repare Therapeutics by 15.0% in the 1st quarter. Sectoral Asset Management Inc. now owns 237,785 shares of the company’s stock worth $3,386,000 after acquiring an additional 31,000 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. bought a new position in shares of Repare Therapeutics in the third quarter valued at approximately $2,269,000.
About Repare Therapeutics
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.